The multiple faces of the partial thromboplastin time APTT

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 12, 2004, Pages 2250-2252

  Rapaport, S I ^a,b   Vermylen, Jozef ^c   Hoylaerts, M ^c   Saito, H ^d   Hirsh, J ^e   Bates, S ^e   Dahlbáck, Bjorn ^f   Poller, Leon ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Leuven ^*  (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e MCMASTER UNIVERSITY   (Canada)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 9; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PREKALLIKREIN; THROMBOPLASTIN;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD CLOTTING TIME; BLOOD SAMPLING; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; ION EXCHANGE CHROMATOGRAPHY; LABORATORY DIAGNOSIS; LABORATORY TEST; MEDICAL RESEARCH; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RISK FACTOR; SCREENING TEST; STANDARDIZATION; VENOUS THROMBOEMBOLISM;

EID: 13244278090     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00994.x     Document Type: Article

References (94)

1. White II GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost, 2003; 1: 2267-70.
2. Langdell RD, Wagner RH, Brinkhous KM. Effect of anti-hemophilic facctor on one-stage clotting tests: a presumptive test for hemophilia and a simple one-stage anti-hemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-47.
3. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-9.
4. Rapaport SI, Fallon M, Goodman J. Survey of a large hemophilic population. Proceedings of the Sixth Congress, International Society of Hematology. New York: Grune & Stratton, 1958: 498-540.
5. Rapaport SI. Evidence that glass increases plasma PTA activity. J Lab Clin Med 1958; 52: 624-33.
6. Ratnoff OD, Rosenbloom JM. The role of Hageman Factor in the initiation of clotting by glass. J Clin Lab Med 1957; 50: 941-2.
7. Ratnoff OD, Rosenbloom JM. Role of Hageman factor in the initiation of clotting by glass: evidence that glass frees Hageman factor from inhibition. Am J Med 1958; 25: 160-8.
8. Waaler BA. Contact activation in the intrinsic blood clotting system. Scand J Clin Invest 1959; 11 (Suppl. 37): 1-134.
9. Margolis J. The kaolin clotting time: a rapid one-stage method for diagnosis of coagulation defects. J Clin Pathol 1958; 11: 405-9.
10. Schiffman S, Rapaport SI, Ware AG, Mehl JW. Separation of plasma thromboplastin antecedent (PTA) and Hageman factor (HF) from human plasma. Proc Soc Exp Biol Med 1960; 105: 453-5.
11. Rapaport SI, Schiffman SA, Patch MJ, Ware AG. A simple, specific one-stage assay for plasma thromboplastin antecedent activity. J Lab Clin Med 1961; 57: 771-80.
12. Rosenthal RL, Dreskin OH, Rosenthal N. Plasma thromboplastin antecedent (PTA) deficiency: clinical, coagulation, therapeutic and hereditary aspects of a new hemophilia-like disease. Blood 1955; 10: 120-31.
13. Rapaport SI, Proctor RR, Patch MJ, Yetrra Y. The mode of inheritence of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18: 149-65.
14. White II GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003; 1: 2267-70.
15. Langdell RD, Wagner RH, Brinhous KM. Effect of anti-hemophilic factor on one-stage clotting tests: a presumptive test for hemophilia and a simple one-stage anti-hemophilic factor assay procedure. J Lab Clin Med 1953; 41: 637-47.
16. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-9.
17. Hemker HC, Giesen PLA, Ramjee M, Wagenvoord R, Béguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb Haemost 2000; 83: 589-91.
18. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci USA 1999; 96: 2311-5.
19. Kawasaki T, Dewerchin M, Lijnen HR, Vreys I, Vermylen J, Hoylaerts MF. Mouse carotid artery ligation induces platelet leukocyte-dependent luminal fibrin, required for neointima development. Circ Res 2001; 88: 159-66.
20. Allen GA, Wolberg AS, Oliver JA, Hoffman M, Roberts HR, Monroe DM. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system. J Thromb Haemost 2004; 2 402-13.
21. Kawasaki T, Kaida T, Arnout J, Vermylen J, Hoylaerts MF. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost 1999; 81: 306-11.
22. White II GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003; 1: 2267-70.
23. Saito H, Kojima T. Factor XII, prekallikrein, high molecular weight kininogen. In: High KA, Roberts HR, eds. Molecular Basis of Thrombosis and Hemostasis. New York: Marcel Dekker, Inc., 1995: 269-85.
24. Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new plasma thromboplastin factor I. Case report, coagulation studies and physicochemical properties. Blood 1965; 26: 521-32.
25. Hattersley PG, Hayse D. Fletcher factor deficiency: a report of three unrelated cases. Br J Haematol 1970; 18: 411-6.
26. Abildgaard CF, Harrison J. Fletcher factor deficiency: family study and detection. Blood 1974; 43: 641-4.
27. Griep MA, Fujikawa K, Nelsestuen GL. Possible basis for the apparent surface selectivity of the contact activation of human blood coagulation factor XII. Biochemistry 1986; 25: 6688-94.
28. Gordon EM, Ratnoff OD, Saito H, Gross S, Jones P. Studies on some coagulation factors (Hageman factor, plasma prekallikrein, and high molecular weight kininogen) in the normal newborn. Am J Pediatr Hematol Oncol 1980; 2: 213-6.
29. Kirkwood TBL, Rizza CR, Snape TJ, Rhymes IL, Austin DEG. Identification of sources of inter-laboratory variation in factor VIII assay. Br J Haematol 1977; 37: 559-68.
30. White II GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003; 1: 2267-70.
31. Struver GP, Bittner DL. The partial thromboplastin time (cephalin time) in anticoagulation therapy. Am J Clin Pathol 1962; 38: 473-81.
32. Harmeling JG, Cordray DR. The activated partial thromboplastin time as a control in heparin therapy. South Med J 1967; 60: 594-8.
33. Wright IS, Beck DF, Marple CD. Myocardial infarction and its treatment with anticoagulants: summary of findings in 1031 cases. Lancet 1954; 1: 92-5.
34. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
35. Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: 1242-5.
36. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-7.
37. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 141: 333-7.
38. Raschke RA, Reilly BM, Guidry JR, Fonatana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a 'standard care' nomogram. A randomized trial. Ann Intern Med 1993; 119: 874-81.
39. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AK, Bill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-95.
40. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9.
41. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001; 161: 385-91.
42. Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med 1997; 157: 2475-9.
43. Rosborough TK. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol 1997; 108: 662-8.
44. Kitchen S, Preston FE. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996; 75: 734-9.
45. Olson JD, Arkin CF, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122 782-98.
46. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2004; (Suppl.): in press.
47. Rachke R, Hirsh J, Guidry J. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low molecular weight heparin. Ann Intern Med 2003; 138: 720-4.
48. Chiu HM, Hirsh J, Yung WL, Regozeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-84.
49. Gould MK, Dembitzer AD, Doyle RI, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep vein thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-9.
50. Quinlan DJ, McQuillan A, Eikelboom JW. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism. A meta-analysis of randomized, controlled trials. Ann Intern Med 2004; 140: 175-83.
51. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST-segment elevation: a meta-analysis. Lancet 2000; 355: 1936-42.
52. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-14.
53. Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-60.
54. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-96.
55. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
56. Anand S, Ginsberg JS, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996; 156: 1667-81.
57. Anand SS, Bates SM, Ginsberg JS, Levine M, Buller H, Prins M, Haley S, Kearon C, Hirsh J, Gent M. Recurrent venous thrombosis and heparin therapy. An evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999; 159: 2029-32.
58. Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnston M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
59. Brandjes DPM, Heijboer H, Buller H, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-9.
60. Mant MJ, O'Brien BD, Thong BL, Hammond GW, Birtwhistle RV, Grace MG. Haemorrhagic complications of heparin therapy. Lancet 1977; 1: 1133-5.
61. The MATISSE Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-702.
62. Francis CW, Ginsberg JS, Berkowitz SC, Bounamoux H, Davidson BL, Eriksson H, Fiessinger J-N, Huisman M, Lundstrom T, Nystrom P for the THRIVE Treatment Study Investigators. Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE Treatment Study. Blood (Suppl.) 2003; 102: 6a (Abstract 7).
63. White II GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003; 1: 2267-70.
64. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anti-coagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
65. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
66. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
67. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
68. Zoller B, Svensson PJ, He X, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.
69. Dahlback B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-400.
70. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994; 343: 1536-8.
71. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-6.
72. Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
73. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
74. Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735-8.
75. Nicolaes GA, Dahlback B. Factor V and thrombotic, disease: description of a Janus-faced protein. Arterioseler Thromb Vasc Biol 2002; 22: 530-8.
76. Nicolaes GA, Dahlback B. Activated protein C resistance FV (Leiden) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003; 17: 37-61, vi.
77. White GC. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003; 1: 2267-70.
78. Thomson JM. The control of heparin therapy by the activated partial thromboplastin time: sensitivity of various thromboplastins to heparin. In: Triplett DA, ed. Standardisation of Coagulation Assays: an Overview. Skokie, IL: College of American Pathologists, 1982: 195-206.
79. Triplett DA. Heparin: Clinical use and monitoring. In: Triplett DA, ed. Laboratory Evaluation of Coagulation. Chicago, IL: American Society of Clinical Pathologists, 1982: 271-313.
80. Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
81. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001; 119: 64S-94S.
82. de Takats G. Heparin and surgery. JAMA 1943; 121: 1246-50.
83. Poller L. A heparin retarded plasma clotting test. Angiology 1954; 5: 21-6.
84. Edson JR, Krivit W, White JG. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967; 70: 463-70.
85. Olson JD, Arkin CA, Brandt JT, Cunningham MT, Giles A, Koepke JA, Witte DL. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122 782-98.
86. Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 on assays of plasma heparin. Br J Haematol 1984; 57: 585-96.
87. Basu D, Gallus AS, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-7.
88. van den Besselaar AMHP, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost 1990; 63: 16-23.
89. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157 2562-8.
90. Poller L. Oral Anticoagulants and Heparin: Standardisation of Laboratory Monitoring in Thrombosis and its Management. Edinburgh: Churchill Livingstone, 1993: 200-13.
91. van der Velde EA, Poller L. The APTT Monitoring of Heparin - The ISTH/ICSH Collaborative Study. Thromb Haemost 1995; 73: 73-81.
92. Requirements for thromboplastins and plasma used to control oral anticoagulant therapy. (Requirements for Biological Substances no. 30, revised 1982.) In: WHO Expert Committee on Biological Standardization. Thirty-Third Report. Annex 3, WHO Technical Report Series no. 687. Geneva: World Health Organization, 1983.
93. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998; 114: 489S-510S.
94. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-9.